Please login to the form below

Not currently logged in
Email:
Password:

Dextroamphetamine

This page shows the latest Dextroamphetamine news and features for those working in and with pharma, biotech and healthcare.

Shire weathers generic Adderall XR challenge

Shire weathers generic Adderall XR challenge

attention deficit-hyperactivity disorder (ADHD) drug Adderall XR (amphetamine and dextroamphetamine).

Latest news

  • Shire's Q3 net profit doubles

    Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR (amphetamine, dextroamphetamine mixed salts).

  • Shire ADHD scholarship programme

    use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved in the US in 2007; and Adderall XR (dextroamphetamine and amphetamine), which was approved in

  • New use cleared for Shire ADHD drug

    The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine dimesylate), which was approved in the US in 2007, and Adderall XR (dextroamphetamine and amphetamine), which was approved

  • Malcolm's Market Eye: 28 July to 3 August 2007

    Shire wants the drug to take over from Adderall XR (amphetamine/dextroamphetamine), its blockbuster drug now threatened by generic competition, because in 2009 it loses patent protection.

  • Malcolm's Market Eye, 27 February 2007

    Shire has gained full control over Vyvanse, as it needs a successor to Adderall XR (amphetamine/ dextroamphetamine extended-release), its biggest-selling ADHD drug, which soon loses patent protection.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....